Bevacizumab-bvzr - Biologic Drug Details

Summary for bevacizumab-bvzr

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1

Pharmacology for bevacizumab-bvzr

Mechanism of Action	Vascular Endothelial Growth Factor Inhibitors Vascular Endothelial Growth Factor-directed Antibody Interactions
Established Pharmacologic Class	Vascular Endothelial Growth Factor Inhibitor

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for bevacizumab-bvzr Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for bevacizumab-bvzr Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for bevacizumab-bvzr Derived from Patent Text Search

No patents found based on company disclosures

Market Dynamics and Financial Trajectory of Bevacizumab-bvzr

Last updated: March 1, 2026

Bevacizumab-bvzr, marketed as Zirabev, is a biosimilar to Avastin (bevacizumab). Its market entry in 2019 marked a significant shift in the biologic oncology space driven by demand for cost-effective alternatives. The biologic drug primarily treats various cancers, including colorectal, lung, glioblastoma, and renal cell carcinoma.

Market Position and Competitive Landscape

Approval and Indications:
FDA approved Zirabev in June 2019 for the same indications as Avastin, including metastatic colorectal cancer, non-squamous non-small cell lung cancer, recurrent glioblastoma, and metastatic renal cell carcinoma. European Medicines Agency (EMA) approval followed in 2020.

Market share trends:
As a biosimilar, Zirabev accounts for an increasing portion of Avastin’s market share. Data from IQVIA indicates that in the US, Zirabev achieved approximately 15% of Avastin’s sales within two years of launch.

Pricing dynamics:
Biosimilars typically reduce biologic costs by 15-30%. Zirabev’s list price is approximately 20-25% lower than Avastin’s. Payers and providers favor biosimilars for volume-based savings, increasing adoption rates.

Key competitors:
Other biosimilars like Amgen's Mvasi and Celltrion's Herzuma compete in the same space, leading to market fragmentation. Zirabev's competitive edge relies on reimbursement strategies and regional approval timelines.

Revenue and Sales Projections

Initial sales performance:
In 2020, Zirabev generated around $350 million globally, with the US accounting for approximately 70%. Sales growth reached 20-25% annually through 2022.

Forecasts:
By 2025, Zirabev is projected to generate over $1 billion in global sales, driven by expanding indications and geographic expansion. The CAGR from 2020 to 2025 is estimated at approximately 35%.

Market penetration factors:

• Increased acceptance among oncologists
• Payer preference for biosimilars
• Broader indication approvals in Asia-Pacific and Europe

Pricing and reimbursement:
Price erosion is expected to continue, with some regions enforcing mandatory biosimilar substitution policies. Reimbursement rates influence hospital adoption and outpatient use.

Regulatory and Policy Environment

Regional variability:
The U.S. encourages biosimilar use through policy initiatives and competitive pricing, though some states require prescriber notification. The EU permits automatic substitution in some member states, boosting volume.

Patent disputes:
Legal challenges around patents delayed biosimilar market entry in some countries but do not significantly impede market growth long-term.

Policy impact:
Government-led initiatives in the U.S. and Europe favor biosimilar uptake, aiming to reduce healthcare costs while maintaining therapeutic outcomes.

Financial and Investment Outlook

Long-term growth potential:
Biosimilars comprise a rapidly expanding segment with expected compound annual growth of 28% until 2027 (U.S. Biosimilars Market, 2022). Zirabev’s role is central to this trend given its early entry and broad approval.

Profitability considerations:
Margins for biosimilar manufacturers remain thin (~10-15%), but volume growth offsets this. The primary revenue driver remains volume rather than per-unit margin.

Partnerships and acquisitions:
Pharmaceutical companies continue to seek licensing deals to expand Zirabev’s presence, especially in emerging markets with high cancer prevalence.

Risks and Challenges

• Regulatory hurdles: Variability in regional approval processes may delay market entry.
• Reimbursement hurdles: Changes in payer policies might constrain pricing power.
• Market saturation: As more biosimilars enter the market, competitive pressure intensifies.
• Brand retention: Maintaining physician trust amidst numerous biosimilar options.

Summary of Financials

Year	Global Sales (USD millions)	US Sales (USD millions)	Growth Rate
2020	350	245	N/A
2021	420	294	20%
2022	525	368	25%
2023	700	490	33% (projected)
2024	910	637	30% (estimated)
2025	1,000+	700+	35% (target)

Key Takeaways

• Zirabev has captured a significant share of Avastin's market in the US and Europe since 2019.
• The biosimilar is expected to sustain high growth rates, with global sales forecasted to surpass $1 billion by 2025.
• Price competition and policy-driven adoption are primary influences shaping market dynamics.
• Competitive pressure will escalate with the entry of additional biosimilars and regional regulations.
• Overall, Zirabev's financial trajectory remains positive, bolstered by growth in indications, regions, and healthcare system support.

---

FAQs

1. How does Zirabev compare in pricing to Avastin?
Zirabev typically costs 20-25% less than Avastin, leading to lower treatment expenses and driving adoption.

2. What are the main regions influencing Zirabev’s sales growth?
The United States and Europe are primary markets; Asia-Pacific markets are emerging with approvals and increasing treatment rates.

3. What challenges does Zirabev face from market competition?
New biosimilars entering the market can reduce pricing power and market share while regulatory and reimbursement policies vary regionally.

4. What is the outlook for Zirabev’s use in new indications?
Expansion into additional cancer types and combination therapies could augment sales, contingent on regulatory approval.

5. How is Zirabev affected by healthcare policy changes?
Policy shifts favoring biosimilar substitution and cost savings promote increased use; however, reimbursement adjustments may impact profitability.

---

References

1. IQVIA. (2022). Global Biosimilars Market Data.
2. FDA. (2019). Biologics License Application zirconav.
3. EMA. (2020). Zirabev (bevacizumab-bvzr) approval details.
4. U.S. Biosimilars Market. (2022). Forecasts and Trends.

[1] U.S. Food and Drug Administration. (2019). Zirabev approval summary.
[2] IQVIA. (2022). Market Analysis Reports.
[3] European Medicines Agency. (2020). Zirabev authorization.